PDGFRA and gastrointestinal stromal tumor: According to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines, IM is not recommended for use in GISTs with PDGFRA exon18 D842V mutation, as this type of GIST is refractory to treatment [15, 16].